Crohn’s Disease Market Research Report: Information by Type (Ileocolitis, Ileitis, Granulomatous colitis, Gastroduodenal Crohn’s Disease, Jejunoileitis, and Perianal Crohn’s Disease), Treatment (Non-Surgical and Surgical), End User (Hospitals and Clinics, Research Institutes, and Others), and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast till 2027
Market Research Future (MRFR) studied the global Crohn’s disease market 2020 across the review period till 2025. Between 2019 and 2025, the Crohn’s disease market can register about 3.3% CAGR. By 2025, the global Crohn’s disease market is expected to earn considerable valuation.
The Crohn’s disease market expansion can be attributed to the increase in preference for symptomatic therapeutic for inflammatory bowel diseases. The rise in occurrence of Crohn's disease and ulcerative colitis is creating the need for new drug formulations for treatment and solution for early diagnosis. The surge in cases among the expanding geriatric group can triggering the need for its therapeutics, which, in turn, can underpin the market rise. The introduction of enhanced drugs and hike in investment for R&D undertakings to develop technology for early diagnosis can promote the Crohn’s disease market growth. However, high cost of treatment, patent expiry of blockbuster drugs, and lack of expertise can restrict growth of the Crohn’s disease market.
Key trends, such as; opting therapeutic over surgeries, arrival of improved drugs, and better disease management for inflammatory bowel diseases are observed in the Crohn’s disease market. may hamper the expansion of the market in the near future. Increase in number of smokers, changes in food habits, and related lifestyle changes are other factors that can contribute to the growth of the market. Furthermore, the growing demand for biologics for treatment can add to the market momentum.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2344
Market Segmentation Study
The segment assessment of the global Crohn’s disease market is based on type, end user, and treatment.
The type-based segments of the global Crohn’s disease market are granulomatous colitis, ileocolitis, ileitis, gastroduodenal Crohn’s disease, perianal Crohn’s disease, and jejunoileitis. The gastroduodenal Crohn’s disease segment is expected to thrive in the near future. Progressive healthcare infrastructure and innovation of healthcare solutions can contribute to treatment benefits of Crohn’s disease.
The treatment-based segments of the Crohn’s disease market are surgical and non-surgical. The non-surgical segment comprises immune system suppressors, anti-inflammatory, and antibiotics among others. The anti-inflammatory sub-segment studies oral 5-aminosalicylates and corticosteroids. The immune system suppressors sub-segment study includes Mercaptopurine, Azathioprine, TNF inhibitors, Natalizumab, Methotrexate, Ustekinumab, and Vedolizumab. The anti-inflammatory segment can garner the largest market share by 2025. The greater efficacy of treatment of anti-inflammatory drugs over analgesic and immunosuppressants, can support the segment upsurge.
The end user-based segments of the Crohn’s disease market are diagnostic centers, hospitals & clinics, and research institutes among others. The hospitals and clinic segment can thrive owing to increase in number of surgeries and rise in hospitalization rates.
Regional Market Summary
In the Americas, the Crohn’s disease market can register decent CAGR by 2025. The growing prevalence of Crohn's disease and hike in per capita healthcare expenses are causes that can promote the market in the region. The rise in number of people afflicted with Crohn’s disease is surging in North American countries. The increase in Crohn's disease cases in the US alone is observed to create high demand for effective treatment that is likely to promote the regional market growth.
In Europe, the Crohn’s disease market can garner considerable revenue by end of the review period. The presence of top-notch marketers can contribute to the EU Crohn’s disease market surge. The existence of well-established healthcare system and the introduction of initiatives by government bodies to develop new and more effective treatment options can contribute to the increasing growth potential of the regional market. Moreover, companies are teaming up with recognized pharma companies to encourages research projects. Thus, innovations and strategic mergers are likely to benefit the market in EU.
In Asia Pacific, Crohn’s disease market is anticipated to register a steady rise throughout the study period. The spreading awareness about patient on Crohn's disease and increase in government initiatives for introduction healthcare reforms can promote APAC Crohn’s disease market. Industrialization, issues with food habits, and innovation in treatment and diagnostic options for Crohn’s disease can add to APAC market expansion in the near future. In Middle East and Africa, the market can experience resistance in expansion due to low per capita disposable income.
Market Key Players
MRFR studied key players of the global Crohn’s disease market. They are; Pfizer Inc., Johnson & Johnson Services Inc., Allergan, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bayer AG, Amgen, Inc., UCB S.A., Eli Lilly and Company, Ferring B.V., Bristol-Myers Squibb, and Hoffman-La Roche.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/crohns-disease-market-2344
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
